- Neumora depression drug fails; EnGene to cut 50% of staffNeumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.BioPharma Dive · 1mo ago↗ source
- How supplement use changed over decadesMedicare-funded weight loss, Utah's lower drunk driving limit, and more health news from Morning RoundsSTAT · 1mo ago↗ source
- STAT+: Verge Labs’ new AI model solves patient stratification problems for neurology clinical trialsAs the saying goes, one man’s trash is another man’s treasure. Or as Verge Labs might put it, one company’s failed clinical trial … is that same company’s new AI…STAT · 1mo ago